Thrombin

AEBSF hydrochloride (Pefabloc SC) is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, thrombin, plasmin, and trypsin.

H-D-Phe-Pip-Arg-pNA dihydrochloride (S-2238) is a sensitive and accurate thrombin detection substrate for measuring antithrombin-heparin cofactor (AT-III).

Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting

Argatroban (MCI-9038), a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs).

Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets thrombin. It binds to exosite 1 of thrombin, inhibiting substrate binding without affecting its catalytic activity. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.

OM-189 is a selective inhibitor of synthetic thrombin.

Thrombin inhibitor 13 (Compound 13a) acts as a covalent reversible inhibitor of thrombin (thrombin, FIIa) with an IC50 of 0.7 nM. This compound prolongs activated partial thromboplastin time (aPTT) and prothrombin time (PT), demonstrating both antithrombotic and anticoagulant properties.

YD-3 is a PAR4 antagonist that significantly inhibits thrombin-induced platelet aggregation in rabbits (IC(50)=28.3 microM). In addition, YD-3 suppresses thrombin-induced proliferation of vascular smooth muscle cells (VSMCs) and reduces neointimal thickening after balloon injury. Through Ras- and ERK1/2-mediated signaling pathways, YD-3 impedes thrombin-driven VSMC proliferation. When analyzed with Western blot, YD-3 primarily inhibits thrombin-induced expression of vascular endothelial growth factor receptor 2 (Flk-1) without affecting extracellular signal-regulated kinase 1/2 phosphorylation. YD-3 could potentially have value in elucidating the pathophysiology of thrombin-induced angiogenesis.

TPO agonist 1, Thrombopoietin (TPO) mimetic, promotes platelet/megakaryocyte production, for thrombocytopenia research.

Flovagatran (TGN 255) is a potent, and selective inhibitor of thrombin and parenteral direct factor II.Flovagatran is used to study venous thromboembolism.

Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.

Efegatran sulfate (LY294468 sulfate) is a potent thrombin inhibitor used in the treatment of thrombotic disorders.

Melagatran is an orally available, direct synthetic thrombin inhibitor that does not require endogenous cofactors other than thrombin.Cost-effective and quality-assured.

Thrombin inhibitor 1 is a potent inhibitor of thrombin (Ki: 0.66 nM, 2xaPTT=0.43 μM).

SCH79797 dihydrochloride is a PAR1 antagonist with IC50 70 nM, Ki 35 nM, antiproliferative, and pro-apoptotic properties.

Antiplatelet agent 3 (Compound K-10) is a compound with antiplatelet aggregation activity, exhibiting IC50 values of 2.55, 3.22, and 2.09 mg/mL for platelet aggregation induced by ADP, AA, and COL, respectively. It holds potential for research in cardiovascular diseases.

(21R)-Argatroban is a diastereomer of Argatroban and acts as an inhibitor of thrombin, exhibiting anticoagulant properties. This compound is useful in research focused on coagulation inhibition.

NAPAP is a thrombin inhibitor with potent anticoagulant activity (Ki: 2.1 nM). It selectively inhibits thrombin through a rapid binding mechanism while exhibiting weaker inhibition of trypsin, Factor Xa, and plasmin. NAPAP can be utilized for research into thrombotic conditions, including venous thrombosis and myocardial infarction.